Core Points - Aurora Cannabis Inc. held its Annual General and Special Meeting of Shareholders on August 8, 2025, with 17,736,521 common shares represented, accounting for 31.53% of the total issued shares [1] - The election results for the Board of Directors showed that all nominees, except for Theresa Firestone, were elected [2] - Following the meeting, Theresa Firestone resigned from the Board effective August 31, 2025, and Michael Singer was appointed as the new Lead Independent Director and Chair of the Human Resources and Compensation Committee [3][4] - Shareholders approved the appointment of Ernst & Young LLP as auditors and amendments to the Company's RSU Plan, PSU Plan, and Share Option Plan, but the advisory vote on executive compensation did not pass [5] Voting Results - Miguel Martin received 5,513,929 votes for his position, while Theresa Firestone received only 2,620,830 votes for her position, leading to her resignation [2][3] - The voting results indicate a strong preference for the other board nominees, with the highest votes for Michael Singer at 5,194,307 [2] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across multiple regions including Canada, Europe, Australia, and New Zealand [7] - The company offers a diverse portfolio of brands in both adult-use and medical cannabis markets, emphasizing high-quality products and innovation [7][8]

Financial Data and Key Metrics Changes - The company reported a record net revenue of $343 million, representing a 27% increase year-over-year, with global medical cannabis revenue increasing by 39% [30][31] - Adjusted gross margin improved to 55% from 49%, benefiting from higher cannabis and plant propagation margins [31] - The company generated record adjusted EBITDA of nearly $50 million and positive free cash flow of about $10 million [30][31] Business Line Data and Key Metrics Changes - International revenue generation surpassed Canadian medical contributions, comprising over 50% of total global medical cannabis revenue, up from 41% in fiscal 2024 [30][31] - The company is positioned as a leader in global medical cannabis, focusing on high-margin segments and operational efficiencies [31][32] Market Data and Key Metrics Changes - The company holds leading market positions in Canada, Australia, Germany, Poland, and the UK, with plans to capitalize on emerging medical cannabis opportunities in underpenetrated markets [32][33] - The global medical cannabis market is estimated to exceed $5 billion, indicating significant growth potential, particularly in Europe and Australia [33][42] Company Strategy and Development Direction - The company’s strategy focuses on a medical cannabis-first approach, aiming for sustainable profitable growth in fiscal 2026 and beyond [33] - Investments in new cultivation technology and strong third-party partnerships are intended to optimize production planning and meet demand [32][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company’s ability to deliver sustainable profitable growth, highlighting a 200% year-over-year growth in adjusted EBITDA for Q1 of fiscal 2026 [36] - The company is committed to maintaining positive free cash flow and operational discipline, with expectations for continued growth in international medical revenue [40][42] Other Important Information - The company has a strong balance sheet with a cash balance of $185 million and operates a debt-free cannabis business, providing a competitive advantage [30] - The company’s operational execution and industry leadership are seen as key factors for future growth [39] Q&A Session Summary Question: What can we expect from adjusted EBITDA patterns moving forward? - Management indicated that fiscal 2025 was a record year for adjusted EBITDA and expressed optimism for continued growth, noting over 200% year-on-year growth in Q1 of fiscal 2026 [36] Question: Why should shareholders continue to invest in the company? - The company has consistently identified and delivered on strategic priorities, focusing on profitable growth and maintaining a strong balance sheet without needing dilutive capital raises [38][39] Question: What can we expect from free cash flow moving forward? - The company expects to remain free cash flow positive, with a 42% increase in free cash flow reported in Q1 of fiscal 2026 compared to the previous year [40][41] Question: Are there still headwinds in international medical revenue? - Management reported strong performance in international medical cannabis, with revenue increasing by 85% year-over-year, and indicated that previous headwinds have subsided [42]

Key Takeaways ACB posted a Q1 loss of 26 cents per share, missing estimates and reversing a prior-year profit.Revenue rose 17.5% Y/Y to $98M, driven by strong international and Canadian medical cannabis sales.International medical cannabis sales surged 84.7% Y/Y.Aurora Cannabis (ACB) reported first-quarter fiscal 2026loss per share from continuing operations of 26 cents against the earnings per share (EPS) of 9 cents in the prior-year quarter. The metric missed the Zacks Consensus Estimate of earnings of 18 ...

Aurora Cannabis Inc. (ACB) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of $0.18. This compares to a loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -205.56%. A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.07, delivering a surprise of -36.36%.Over the last four quarters, the company has surpa ...

Aurora Cannabis (ACB) Q1 2026 Earnings Call August 06, 2025 08:00 AM ET Speaker0Greetings, and welcome to Aurora Cannabis Incorporated Fiscal First Quarter twenty twenty six Results Conference Call. All participants will be in a listen only mode. A question and answer session will follow the formal presentation. The conference is being recorded today, Wednesday, 08/06/2025. I would now like to turn the conference over to your host, Kevin Nyland, Senior Director of Strategic Finance and Investor Relations.Pl ...

Investor Presentation FY26 Q1 June 2025 Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend ...

Key Takeaways ACB's medical cannabis sales likely rose in Germany and Australia, supported by new product launches.Regulatory disruptions in Poland and seasonal market fluctuations might have dampened ACB's Q2 revenue growth.Margins remain robust with positive EBITDA, but ACB's QoQ sales dip calls for cautious near-term outlook.Aurora Cannabis (ACB) is slated to release first-quarter fiscal 2026 results on Aug. 6, before market open. The Zacks Consensus Estimate for earnings and revenues is pegged at 18 cen ...

Your vote is important no matter how many shares you own. Please vote today. Shareholders who have questions or need assistance with voting their shares should contact Aurora's strategic advisor and proxy solicitation agent, Laurel Hill Advisory Group, by telephone at 1-877-452-7184 or by email at [email protected].EDMONTON, AB, July 30, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, would like to remind ...

Financial Performance - Profit before tax (PBT) reached approximately VND 10.7 trillion in 1H25, a 2% year-over-year increase[93] - The Return on Equity (ROE) stood at approximately 20.6%, positioning ACB among the top-performing banks[27, 93] - Net Interest Income (NII) for 1H25 was VND 13043 billion, a 6% decrease year-over-year[33] - Non-Interest Income (NFI) grew by 39% year-over-year, reaching VND 4164 billion in 1H25, driven by investment and FX activities[39] Asset Quality and Growth - Credit growth was 9.1% year-to-date, with total lending reaching approximately VND 634 trillion[10, 93] - Deposit growth was 5.6% year-to-date, with total deposits reaching approximately VND 567 trillion[16, 93] - The Non-Performing Loan (NPL) ratio decreased to 1.27%[47] - The CASA ratio increased to 22.5% in Q2[20] Strategic Initiatives - The investment portfolio accounted for 16% of total assets[23] - Operating costs were effectively managed, maintaining the Cost-to-Income Ratio (CIR) at 32%[42, 43] - The bank launched a VND 2000 billion green/social credit package[90] Outlook - The company projects credit growth of +16%-18% vs 2024[95]

Core Viewpoint - Aurora Cannabis Inc. is set to announce its financial results for the first quarter of 2026 on August 6, 2025, and will host a conference call to discuss these results [1][5]. Group 1: Conference Call Details - The conference call is scheduled for August 6, 2025, at 8:00 a.m. Eastern Time and 6:00 a.m. Mountain Time [2]. - Miguel Martin, Executive Chairman and CEO, along with Simona King, CFO, will lead the conference call and Q&A session [2]. Group 2: Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Edmonton, Alberta, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [3]. - The company offers a diverse portfolio of brands, including adult-use brands like Drift and San Rafael '71, and medical brands such as MedReleaf and CanniMed [3]. - Aurora holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [3]. Group 3: Stock Information - Aurora's common shares are traded on NASDAQ and TSX under the symbol "ACB" [4].